About Dana-Farber Cancer Institute
Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research.
Our equal commitment to research and patient care is unique among cancer centers and results in an extraordinary level of collaboration between our scientists and clinicians, speeding the translation of laboratory discoveries into lifesaving treatments for patients all over the world.
The Institute employs over 4,000 people supporting more than 380,000 patient visits a year, is involved in 760 clinical trials, and is internationally renowned for its blending of research and clinical excellence. Our expertise in these two aspects of the fight against cancer uniquely positions it to develop and test the next generation of cancer therapies in both the laboratory and the clinic.
Dana-Farber is a principal teaching affiliate of Harvard Medical School and a founding member of the Dana-Farber/Harvard Cancer Center and the Center for AIDS Research at Harvard University.
Dana-Farber faculty access resources and scientific expertise in highly specialized fields through the Institute’s associations with the Harvard Stem Cell Institute, Harvard’s NIH Clinical and Translational Science Center, and the Broad Institute, a center of genomic research where several Dana-Farber faculty members have joint appointments.
Providing advanced training in cancer treatment and research for an international faculty, the Institute conducts community-based programs in cancer prevention, detection, and control throughout New England, and maintains joint programs with other Boston institutions affiliated with Harvard Medical School and the Partners Health Care System, including Brigham and Women's Hospital, Boston Children's Hospital, and Massachusetts General Hospital.